Vanda Pharmaceuticals | VNDA - Sales Revenues


Vanda Pharmaceuticals reported $198.77M in Sales Revenues for its fiscal quarter ending in December of 2024.





Sales Change Date
Acadia Pharmaceuticals USD 307.96M 39.9M Jun/2026
Agios Pharmaceuticals USD 44.74M 25.94M Jun/2026
Akebia Therapeutics USD 57.62M 1.14M Dec/2025
Alnylam Pharmaceuticals USD 1.29B 120M Jun/2026
Anika Therapeutics USD 30.62M 2.8M Dec/2025
Arrowhead Research USD 75.23M 1.49M Jun/2026
AstraZeneca USD 15.38B 90M Jun/2026
Bristol-Myers Squibb USD 12.97B 1.48B Jun/2026
Eli Lilly USD 22.97B 3.17B Jun/2026
Enanta Pharmaceuticals USD 16.96M 50.68M Dec/2024
Halozyme Therapeutics USD 481M 104M Jun/2026
Heron Therapeutics USD 40.59M 2.38M Dec/2025
Insmed USD 425.49M 119.53M Jun/2026
J&J USD 25.31B 1.21B Jun/2026
Lexicon Pharmaceuticals USD 5.49M 8.69M Dec/2025
Ligand Pharmaceuticals USD 83.7M 31.98M Jun/2026
Merck USD 16.6B 310M Jun/2026
Minerva Neurosciences USD 0 0 Sep/2024
Moderna USD 100M 289M Jun/2026
Novartis USD 13.11B 750M Mar/2026
Pfizer USD 15.03B 530M Jun/2026
PTC Therapeutics USD 361M 88M Jun/2026
Puma Biotechnology USD 80.54M 33.46M Sep/2024
Sangamo BioSciences USD 356K 125K Jun/2024
Sanofi EUR 11.95B 710M Jun/2026
Takeda JPY 1.22T 130B Jun/2026
Teva Pharmaceutical Industries USD 12.67B 900M Jun/2026
Ultragenyx Pharmaceutical USD 214M 78M Jun/2026
Vanda Pharmaceuticals USD 198.77M 151.12M Dec/2024
Veracyte USD 150.32M 11.25M Jun/2026